Finally, PD-1 antagonists such as nivolumab and CSFR1 inhibitors such as pexidartinib are relatively new to the field of bone cancer pain but show promising results in preclinical models that warrant further investigation. This evidence concerns the gene PDCD1 and bone cancer.